Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
  • C07C233/00—Carboxylic acid amides
  • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
  • C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
  • C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/06—Antiarrhythmics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

• Ar represents substituted or unsubstituted aryl, wherein the optional substituents are selected from alkyl, hydroxy or alkoxy or, if attached to adjacent carbon atoms any two substituents together with the carbon atoms to which they are attached may form a fused heterocyclic ring of five to six atoms wherein one, two or three of the said atoms are oxygen or nitrogen;
• A represents a C1.4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 Ci . ⁇ alkyl groups;
• R ⁇ represents hydrogen, alkyl, alkenyl or cycloalkyl; one or two of the group of R2, R3 and R4 represents nitro the remaining members of the group of R2, R3 and R4 represent hydrogen; X represents a -CO-NH- moiety; and
• Z represents C2-.4 n-alkylene group wherein each carbon is optionally substituted by 1 or 2 C ⁇ . alkyl groups.
• Example 2 of WO 96/13479 is the hydrochloride salt, N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'the Hydrochloride'), the disclosed melting point of which is 141-2°C.
• N-[3-[[2-(3,4- dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride exists in a novel polymorphic form which form is particularly suitable for bulk preparation and handling and is also indicated to have superior formulation properties.
• This novel polymorphic form can be prepared by an efficient, economic and reproducible process particularly suited to large scale preparation.
• the novel polymorphic form also has useful pharmaceutical properties and is considered to be a useful anti-arrhythmic agent having combined Class Ill/Class IV anti- arrhythmic properties, therefore showing an improved pharmacological profile over pure class III anti-arrhythmic agents, in particular showing a low proarrhythmic potential, readily restoring the contractile function of the ischaemic myocardium. It is considered to be particularly useful for the treatment of atrial or ventricular cardiac arrhythmias.
• the present invention provides a novel polymorphic form of N-[3- [[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride (hereinafter also referred to as 'Compound (I)') characterised in that it:
• the present invention encompasses Compound (I) isolated in a purified form or in an impure form, such as when admixed with other materials, for example the known form of the Hydrochloride or any other material.
• Compound (I) is in a puried form, especially a crystalline form.
• the invention also provides a process for preparing the novel polymorphic form of N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4-nitrobenzamide hydrochloride, characterised in that N-[3-[[2-(3,4-dimethoxyphenyl)ethyl]amino]propyl]-4- nitrobenzamide hydrochloride is crystallized from acetonitrile and thereafter the acetonitrile removed, from the product. Preferably the acetonitrile is removed by drying, suitably in vacuo.
• the crystals are preferably dried at an elevated temperature, for example at 60°C and over an extended period, usually greater than 12 hours for example 36 hours.
• Crystallisation and any recrystallisation is generally carried out at low to ambient temperature, suitably at ambient temperature.
• the Hydrochloride is dissolved in acetonitrile at an elevated temperature, for example the reflux temperature of the solvent.
• crystallisation is initiated by allowing the solution to cool to ambient temperature.
• Compound (I) is prepared from a solution of the Hydrochloride in acetonitrile at an elevated temperature such as 60°C, allowing the product to crystallise on cooling and thereafter drying the resulting product in vacuo at 60°C. Purification of Compound (I) is also suitably effected by recrystallization of impure Compound (I) using this last mentioned procedure.
• the Hydrochloride is prepared according to known procedures such as those disclosed in WO 96/13479.
• the disclosures of WO 96/13479 are incorporated herein by reference.
• cardiac arrhythmia relates to any variation from the normal rhythm of heart beat, including, without limitation, sinus arrhythmia, premature heartbeat, heartblock, fibrillation, flutter, tachycardia, paroxysmal tachycardia and premature ventricular contractions.
• the present invention accordingly provides Compound (I) for use as an active therapeutic substance.
• the present invention provides Compound (I) for use in the treatment of and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders.
• Compound (I) may be administered per se or, preferably, as a pharmaceutical composition also comprising a pharmaceutically acceptable carrier.
• the present invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising Compound (I) and a pharmaceutically acceptable carrier therefor.
• Compound (I) is normally administered in unit dosage form.
• An amount effective to treat the disorder hereinbefore described depends upon such factors as the efficacy of a Compound (I) chosen, the nature and severity of the disorders being treated and the weight of the mammal.
• a unit dose will normally contain 0.1 to 500 mg for example 2 to 50 mg, of the compound of the invention.
• Unit doses will normally be administered once or more than once a day, for example 2,3,4,5 or 6 times a day, more usually 2 to 4 times a day, such that the total daily dose is normally in the range, for a 70 kg adult of 0.1 to 2500 mg, more usually 1 to 1000 mg, for example 1 to 200 mg, that is in the range of approximately 0.02 to 3 mg/kg/day, more usually 0.1 to 3 mg/kg/day, for example 0.15 to 2 mg/kg/day.
• the active compound may be administered by any suitable route, e.g. by the oral, parenteral or topical routes.
• the compound will normally be employed in the form of a pharmaceutical composition in association with a human or veterinary pharmaceutical carrier, diluent and/or excipient, although the exact form of the composition will naturally depend on the mode of administration.
• compositions are prepared by admixture and are suitably adapted for oral, parenteral or topical administration, and as such may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, pastilles, reconstitutable powders, injectable and infusable solutions or suspensions, suppositories and transdermal devices.
• Orally administrable compositions are preferred, in particular shaped oral compositions, since they are more convenient for general use.
• Tablets and capsules for oral administration are usually presented in a unit dose, and contain conventional excipients such as binding agents, fillers, diluents, tabletting agents, lubricants, disintegrants, colourants, flavourings, and wetting agents.
• the tablets may be coated according to well known methods in the art.
• Suitable fillers for use include cellulose, mannitol, lactose and other similar agents.
• Suitable disintegrants include starch, polyvinylpyrrolidone and starch derivatives such as sodium starch glycollate.
• Suitable lubricants include, for example, magnesium stearate.
• Suitable pharmaceutically acceptable wetting agents include sodium lauryl sulphate.
• Solid oral compositions may be prepared by conventional methods of blending, filling, tabletting or the like. Repeated blending operations may be used to distribute the active agent throughout those compositions employing large quantities of fillers. Such operations are, of course, conventional in the art.
• Oral liquid preparations may be in the form of, for example, aqueous or oily suspensions, solutions, emulsions, syrups, or elixirs, or may be presented as a dry product for reconstitution with water or other suitable vehicle before use.
• Such liquid preparations may contain conventional additives such as suspending agents, for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate, or acacia; non-aqueous vehicles (which may include edible oils), for example, almond oil, fractionated coconut oil, oily esters such as esters of glycerine, propylene glycol, or ethyl alcohol; preservatives, for example methyl or propyl ⁇ -hydroxybenzoate or sorbic acid, and if desired conventional flavouring or colouring agents.
• suspending agents for example sorbitol, syrup, methyl cellulose, gelatin, hydroxyethylcellulose, carboxymethyl cellulose, aluminium stearate gel or hydrogenated edible fats, emulsifying agents, for example lecithin, sorbitan monooleate
• fluid unit dose forms are prepared containing a compound of the present invention and a sterile vehicle.
• the compound depending on the vehicle and the concentration, can be either suspended or dissolved.
• Parenteral solutions are normally prepared by dissolving the active compound in a vehicle and filter sterilising before filling into a suitable vial or ampoule and sealing.
• adjuvants such as a local anaesthetic, preservatives and buffering agents are also dissolved in the vehicle.
• the composition can be frozen after filling into the vial and the water removed under vacuum.
• Parenteral suspensions are prepared in substantially the same manner except that the active compound is suspended in the vehicle instead of being dissolved and sterilised by exposure to ethylene oxide before suspending in the sterile vehicle.
• a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the active compound.
• the composition may be in the form of a transdermal ointment or patch for systemic delivery of the compound and may be prepared in a conventional manner, for example, as described in the standard textbooks such as 'Dermatological Formulations' - B.W. Barry (Drugs and the Pharmaceutical Sciences - Dekker) or Harrys Cosmeticology (Leonard Hill Books).
• compositions may contain further active agents such as anti-hypertensive agents and diuretics.
• active agents such as anti-hypertensive agents and diuretics.
• the compositions will usually be accompanied by written or printed directions for use in the medical treatment concerned.
• the term 'pharmaceutically acceptable embraces compounds, compositions and ingredients for both human and veterinary use: for example the term 'pharmaceutically acceptable salt' embraces a veterinarily acceptable salt.
• the present invention further provides a method for the treatment and/or prophylaxis of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders in a human or non-human mammal which comprises administering an effective, non-toxic, amount of Compound (I) to a human or non-human mammal in need thereof.
• the active ingredient may be administered as a pharmaceutical composition hereinbefore defined, and this forms a particular aspect of the present invention.
• Compound (I) may be taken in doses, such as those described above. Similar dosage regimens are suitable for the treatment and/or prophylaxis of non-human mammals.
• the present invention provides the use of Compound (I) for the manufacture of a medicament for the treatment of arrhythmia, especially cardiac arrhythmia such as ventricular arrhythmia, and also ischaemic rhythm disorders. No adverse toxicological effects are indicated when Compound (I) is administered in the above mentioned dosage ranges.
• the Hydrochloride was prepared as disclosed in Example 2 of WO 96/13479. 173g of crude Hydrochloride was dissolved at reflux in 1.3 liter of acetonitrile.
• a PW1710 X-ray powder diffractometer (Cu X-ray source) was used to generate the spectrum using the following acquisition conditions:
• Step size 0.005 °2 ⁇
• the infrared absorption spectrum of a mineral oil dispersion of Compound (I) was obtained using a Perkin-Elmer PE2000 spectrometer at 2 cm -1 resolution.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Engineering & Computer Science (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Medicinal Chemistry (AREA)
• Animal Behavior & Ethology (AREA)
• Cardiology (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Veterinary Medicine (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Life Sciences & Earth Sciences (AREA)
• Heart & Thoracic Surgery (AREA)
• General Health & Medical Sciences (AREA)
• Urology & Nephrology (AREA)
• Vascular Medicine (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (3)

Publications (1)

Family

ID=10862442

Family Applications (1)

Country Status (18)

Families Citing this family (2)

Family Cites Families (2)

• 1999
  • 1999-10-08 GB GBGB9923933.7A patent/GB9923933D0/en not_active Ceased
• 2000
  • 2000-10-06 KR KR1020027004451A patent/KR20020043618A/ko not_active Application Discontinuation
  • 2000-10-06 CA CA002386845A patent/CA2386845A1/en not_active Abandoned
  • 2000-10-06 JP JP2001530092A patent/JP2003511437A/ja active Pending
  • 2000-10-06 HU HU0203582A patent/HUP0203582A2/hu unknown
  • 2000-10-06 CZ CZ20021189A patent/CZ20021189A3/cs unknown
  • 2000-10-06 EP EP00964535A patent/EP1218334A1/en not_active Withdrawn
  • 2000-10-06 AU AU75460/00A patent/AU7546000A/en not_active Abandoned
  • 2000-10-06 CN CN00813990A patent/CN1384817A/zh active Pending
  • 2000-10-06 BR BR0014591-2A patent/BR0014591A/pt not_active Application Discontinuation
  • 2000-10-06 WO PCT/GB2000/003847 patent/WO2001027071A1/en active IP Right Grant
  • 2000-10-06 IL IL14896600A patent/IL148966A0/xx unknown
  • 2000-10-06 PL PL00354137A patent/PL354137A1/xx not_active Application Discontinuation
  • 2000-10-06 TR TR2002/00949T patent/TR200200949T2/xx unknown
  • 2000-10-06 MX MXPA02003516A patent/MXPA02003516A/es unknown
• 2002
  • 2002-04-05 ZA ZA200202679A patent/ZA200202679B/en unknown
  • 2002-04-05 NO NO20021639A patent/NO20021639L/no not_active Application Discontinuation
  • 2002-12-27 HK HK02109370.9A patent/HK1049147A1/zh unknown

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events